Results 101 to 110 of about 337 (145)

Efficacy and safety of FLT3 inhibitors in monotherapy of hematological and solid malignancies: a systemic analysis of clinical trials

Frontiers in Pharmacology
Introduction: FLT3 mutations are closely associated with the occurrence of hematological and solid malignancies, especially with acute myeloid leukemia.
Yuying Zhao, Xuedi Zhang, Xiaoyan Ding, Ying Wang, Zhenpeng Li, Ronglan Zhao, Hai-En Cheng, Yanli Sun   +7 more
doaj   +1 more source

Supplemental information for: Inhibition of CSF1R and KIT with pexidartinib reduces inflammatory signaling and cell viability in endometriosis

<p>Endometriosis is a common and debilitating disease, affecting ~170 million women worldwide. Affected patients have limited therapeutic options such as hormonal suppression or surgical excision of the lesions, though therapies are often not ...
Cope, Dominique, Detti, Laura, Yuan, Fei, Dunn, Timothy, Matzuk, Martin, Alpuing-Radilla, Linda, Guan, Xiaoming, Creighton, Chad, Sirupangi, Tirupataiah, Liao, Zian, Tang, Suni, Parks, Sydney, Masand, Ramya, Monsivais, Diana   +13 more
core   +1 more source

Recurrent diffuse tenosynovial giant cell tumor of the posterior knee: a rare presentation with synovial herniation (Baker’s cyst) in a young patient

BMC Musculoskeletal Disorders
Introduction Tenosynovial giant cell tumor (TGCT), previously referred to as pigmented villonodular synovitis (PVNS), is a rare, locally aggressive proliferative disorder of the synovium.
Khalid AlHarbi, Sultan AlHussain
doaj   +1 more source

Pexidartinib and Nintedanib Combination Therapy Targets Macrophage Polarization to Reverse Pulmonary Fibrosis: A Preclinical Study

Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive interstitial lung disease with limited therapeutic options and increasing global incidence, with a median survival of only 2–5 years.
Jeeyong Lee, Jae-Kyung Nam, Hae-June Lee, Seo, Seungyoul, Lee, Hae-June, Lee, Jeeyong, Min-Sik Park, Ji-Hee Kim, Hyung Chul Ryu, Park, Min-Sik, Lee, Yoon-Jin, Ryu, Hyung Chul, Yoon-Jin Lee, Kim, Ji-Hee, Seungyoul Seo, Nam, Jae-Kyung   +15 more
core   +1 more source

Medical Management of Pigmented Villonodular Synovitis of the Right Ankle and Foot

Translation
Brianna Bailey, Divya Vijendra
doaj   +1 more source

Tenosynovial Giant Cell Tumor Treatment Revolution: Vimseltinib's Edge Over Pexidartinib

Medicine Advances
Muhammad Affan Abid, Syed Azfar Hussain, Muhammad Ali Kamal   +2 more
doaj   +1 more source

A phase 4, multicenter, global clinical study to evaluate discontinuation and rechallenge of pexidartinib in patients with tenosynovial giant cell tumor previously treated with pexidartinib [PDF]

Cancer
AbstractBackgroundPexidartinib is effective in patients with tenosynovial giant cell tumor (TGCT) for whom surgery is not feasible. Durability of response after discontinuation of pexidartinib and the safety and efficacy of restarting pexidartinib have not been previously recorded. This phase 4 study was designed to mimic the real‐world experience with
Hans J. Gelderblom, Silvia Stacchiotti, Chia-Chi Lin   +2 more
exaly   +6 more sources

Mechanistic study of pexidartinib-induced toxicity in human hepatic cells

Chemico-Biological Interactions
Pexidartinib, a tyrosine kinase inhibitor, was approved by the U.S. Food and Drug Administration in 2019 for treating adult patients with symptomatic tenosynovial giant cell tumors. Because of its hepatotoxicity risks, pexidartinib received a boxed warning; however, mechanistic studies on this hepatotoxicity remain limited.
Xiaobo He, Matthew Bryant, Nan Mei
exaly   +4 more sources

Pexidartinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor: safety and efficacy

Expert Review of Anticancer Therapy, 2020
Tenosynovial giant cell tumor (TGCT) is a benign clonal neoplastic proliferation arising from the synovium often causing pain, swelling, joint stiffness, and reduced quality of life. The optimal treatment strategy in patients with diffuse-type TGCT (dt-TGCT) is evolving.
Alessandra Longhi, Davide Maria Donati, Emanuela Palmerini   +2 more
exaly   +6 more sources

Pexidartinib: first approved systemic therapy for patients with tenosynovial giant cell tumor [PDF]

Future Oncology, 2020
Pexidartinib is an orally administered small molecule tyrosine kinase inhibitor. Phase III ENLIVEN study results provided clinical evidence for US FDA approval for treatment of adult patients with symptomatic tenosynovial giant cell tumor associated with severe morbidity or functional limitations and not amenable to improvement with surgery ...
Hans J. Gelderblom
exaly   +5 more sources